Creative Medical rises on positive long-term data for StemSpine procedure
14/02/2023 14:07
** Shares of biotech firm Creative Medical Technology
Holdings Inc CELZ.O rise 12.24% to $0.82 in premarket trading
** Co says three-year follow-up data confirms significant
efficacy and no serious adverse effects in patients using its
StemSpine procedure for chronic lower back pain
** StemSpine is a patented procedure that utilizes a
patient's own bone marrow aspirate for the treatment of chronic
lower back pain
** StemSpine procedure resulted in a continued efficacy rate
of 87% in the treated patients - CELZ
** Co's stock lost 82.8% in 2022
(Reporting by Pratik Jain in Bengaluru)
((Pratik.Jain@thomsonreuters.com;))
Recent news on Creative Medical Technology Holdings
See all newsBrief: Creative Medical Technology Buys 4 Million Biodefense Shares For $200,000 Cash And 1 Million Shares On Sept 24
Brief: Creative Medical Technology Holdings Successfully Completes Enrollment And Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation And Phase 3 Planning
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
NASDAQ RESUMED AT 11:07 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:02 AM